DISEASE INDICATIONS: Chronic Obstructive Pulmonary Disease, Asthma

MANUFACTURER: GlaxoSmithKline

USAGE: Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Pharmaceuticals and Medical Devices Agency (PMDA)

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is prescribed as a continuous, maintenance therapy for individuals with asthma and chronic obstructive pulmonary disease (COPD).